Supplemental Table S1. Comparative risk of adverse kidney outcomes between sirolimus and MMF.

	AKD			EGFR decline > 30% from baseline		
	aHR	**95% CI**	***p*-value**	**aHR**	**95% CI**	***p*-value**
Sirolimus vs MMF	1.04	(0.70–1.55)	0.83	2.09	(1.33–3.28)	0.001
Baseline eGFR, mL/min/1.73 m^2						
<90	1.00	reference		1.00	reference	
≧90	1.71	(1.02–2.89)	0.04	2.52	(1.42–4.49)	0.002
Baseline characteristic						
Male vs female	0.86	(0.54–1.39)	0.55	0.89	(0.54–1.46)	0.64
Age, years	1.03	(1.01–1.06)	<0.01	1.05	(1.02–1.07)	0.001
Alcohol	1.14	(0.64–2.04)	0.65	0.61	(0.31–1.22)	0.16
BMI	0.99	(0.95–1.04)	0.72	0.97	(0.92–1.02)	0.26
MELD score	1.03	(1.00–1.06)	0.03	1.03	(1.00–1.06)	0.06
Hypertension	1.10	(0.60–1.99)	0.76	1.04	(0.55–1.96)	0.91
DM	1.29	(0.78–2.15)	0.32	1.01	(0.59–1.74)	0.97
HBV	0.80	(0.47–1.34)	0.39	1.17	(0.66–2.07)	0.59
HCV	0.92	(0.53–1.60)	0.77	0.84	(0.46–1.54)	0.57
HCC	1.03	(0.61–1.76)	0.90	1.07	(0.61–1.88)	0.81
Labs						
Baseline albumin, g/dl	-	-	-	0.77	(0.61–1.88)	0.81
Baseline Hb, g/dl	1.03	(0.66–1.60)	0.91	0.93	(0.83–1.04)	0.19
Proteinuria> 1+	1.13	(0.54–2.36)	0.75	0.84	(0.37–1.91)	0.68
Tacrolimus trough level (index date)	1.09	(0.98–1.22)	0.12	0.92	(0.81–1.04)	0.17
Tacrolimus trough level (6 month)				1.02	(0.93–1.12)	0.67
prior medications						
ACEI/ARB	0.71	(0.39–1.30)	0.27	1.44	(0.81–2.55)	0.21
Statins	1.34	(0.57–3.17)	0.50	2.84	(1.35–5.99)	0.006
Diuretic	2.69	(0.31–23.22)	0.37	1.26	(0.15–10.7)	0.83
NSAIDs	0.79	(0.1– 6.09)	0.82	2.54	(0.54–11.9)	0.24

ACEI: angiotensin-converting enzyme inhibitor; aHR: adjusted hazard ratio; AKD: acute kidney disease; ARB: angiotensin receptor blocker; BMI: body mass index; CI: confidence interval; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular carcinoma; MELD: model for End-Stage liver disease; MMF: mycophenolate mofetil; NSAID: nonsteroidal anti-inflammatory drugs.